Evidence map›Paper›PMID 36974333›Full record

ArticleScientific African2023

Herbal supplements as treatment options for COVID-19: A call for clinical development of herbal supplements for emerging and re-emerging viral threats in Sub-Saharan Africa.

Augustine Anayochukwu Onyeaghala, Arinze Favour Anyiam, Danladi Chiroma Husaini, Emmanuella Ogechi Onyeaghala, Ejeatuluchukwu Obi

Open access · goldAbstract read
In one paragraph

Article in Scientific African, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Augustine Anayochukwu OnyeaghalaUnit of Clinical Chemistry, Department of Medical Laboratory Science, University College Hospital, Ibadan, Nigeria.
Arinze Favour AnyiamDepartment of Medical Laboratory Science, Thomas Adewumi University, Oko, Kwara State, Nigeria.
Danladi Chiroma HusainiDepartment of Allied Health (Pharmacy), Faculty of Health Sciences, University of Belize, Central America, Belize.
Emmanuella Ogechi OnyeaghalaDepartment of Medical Laboratory Science, Achievers University, Owo, Ondo State, Nigeria.
Ejeatuluchukwu ObiDepartment of Pharmacology and Therapeutics, Faculty of Basic Clinical Science, College of Health Science, Nnamdi Azikiwe University, Nnewi, Campus, Nigeria.
Achievers University · NGNnamdi Azikiwe University · NGThomas Adewumi UniversityUniversity College Hospital, Ibadan · NGUniversity of Belize · BZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of Corona virus Disease 2019 (COVID-19) distorted health systems of many countries. Efforts have been made to either develop new treatment solutions such as vaccines or repurpose previously adopted drugs. Challenges in accessing available treatment, inadequate, non-existent, or overstretched healthcare facilities, long COVID disease, cultural practices and beliefs about vaccination, vaccine hesitancy, availability, accessibility and perceived safety of herbal supplements seem to be major factors propelling individuals to use herbal supplements. Published reports advocating for clinical development of herbal supplements for COVID-19 and other emerging and re-emerging viral diseases are sparse. This paper aims to review the pathogenesis of COVID-19, use of herbal products during the pandemic and make case for clinical development of herbal supplements through the adoption of modern and acceptable technologies and research processes. This was a scoping review. Database searches of Google Scholar, PubMed and ResearchGate among others were performed using related keywords to identify relevant journals and lists of primary articles. Clinical trial databases:-Clinicaltrial.gov, Pan African Clinical Trial Registry (PACTR) and WHO international clinical trial registry (ICTRP) were reviewed to extract data. The use of herbal supplements during COVID-19 was not only peculiar to individuals living in Sub-Saharan Africa, but a global practice. Herbal supplements recommended to manage COVID-19 have not been validated using clinical trials. Available data showed that the number of herbal supplements undergoing clinical trial for COVID-19 indication in Africa was low. The availability of medicinal plants in Sub-Saharan Africa if well explored has great potentials to address various emerging and re-emerging viral diseases confronting the region. The economic potential of clinically validated herbal supplements are huge, and tapping into this opportunity created by preference of population to herbal supplement could increase export of herbal supplement and gross domestic product (GDP) of respective countries in Africa.

Indexed as

Clinical DevelopmentCOVID-19Herbal MedicineHerbal ProductsHerbal SupplementsSARS-CoV-2

Identifiers

PMID36974333
PMCPMC9985929
OpenAlexW4323275424

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.